Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis

Selective Janus kinase inhibitors come of age

(2019) John J. O’Shea et al.   Nature Reviews Rheumatology

A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis

(2019) Katie Bechman et al.   RHEUMATOLOGY

Tofacitinib in patients with moderate to severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study

(2018) F. Valenzuela et al.   BRITISH JOURNAL OF DERMATOLOGY

Clinical Images: Elderly-onset varicella pneumonia in a patient with rheumatoid arthritis treated with tofacitinib

(2018) Nobuya Abe et al.   Arthritis & Rheumatology

First Reported Case of Pulmonary Arterial Hypertension Secondary to Tofacitinib Treatment for Undifferentiated Arthritis

(2018) Pauline Habib et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events

(2017) Mônica Simon Prado et al.   Expert Opinion on Drug Metabolism & Toxicology

Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study

(2017) Yoshiya Tanaka et al.   Modern Rheumatology

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

(2017) Daniella M. Schwartz et al.   NATURE REVIEWS DRUG DISCOVERY

The emerging safety profile of JAK inhibitors in rheumatic disease

(2017) Kevin L. Winthrop   Nature Reviews Rheumatology

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

(2016) Jonathan AC Sterne et al.   BMJ-British Medical Journal

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

(2016) Jonathan AC Sterne et al.   BMJ-British Medical Journal

What is the future of targeted therapy in rheumatology: biologics or small molecules?

(2014) Attila Mócsai et al.   BMC Medicine

A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases

(2014) Jason J Lee et al.   ARTHRITIS RESEARCH & THERAPY

New therapies in the management of rheumatoid arthritis

(2011) Maya H Buch et al.   CURRENT OPINION IN RHEUMATOLOGY

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

(2008) J Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

(2008) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate

(2008) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM